Trends in Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia, 2004 to 2013: the Urologic Diseases in America Project

Welliver, Charles; Feinstein, Lydia; Ward, Julia B.; Fwu, Chyng‐Wen; Kırkalı, Ziya; Bavendam, Tamara; Matlaga, Brian R.; McVary, Kevin T.

doi:10.1097/ju.0000000000000499

Cited by 39 publications

(37 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Benign prostatic hyperplasia (BPH) is the most common urinary system disease in elderly men [1], and its main pathological manifestations are proliferative hypertrophy and nodule formation in the transition zone of the prostate. According to American epidemiological studies, the number of patients diagnosed with BPH reached 30,555,010 cases between 2004 and 2013 [2]. The occurrence and development of BPH are closely related to age.…”

Section: Introductionmentioning

confidence: 99%

Review of the Roles and Interaction of Androgen and Inflammation in Benign Prostatic Hyperplasia

Tong

Zhou

2020

Mediators of Inflammation

View full text Add to dashboard Cite

The lower urinary tract symptoms (LUTSs) and acute urinary retention (AUR) caused by benign prostatic hyperplasia (BPH) can seriously affect the quality of life of elderly men. Studies suggest that both androgens and inflammation greatly influence the occurrence and development of BPH in most patients. These two factors combined can also affect each other, leading to pathological changes in the stromal and epithelial tissue of the prostate transition zone in BPH patients. DHT in the prostate tissue of BPH patients may activate a chronic inflammatory response in the prostate, amplifying the expression of inflammatory factors and upregulating the proliferation ability of prostate tissue.

show abstract

Section: Introductionmentioning

confidence: 99%

Review of the Roles and Interaction of Androgen and Inflammation in Benign Prostatic Hyperplasia

Tong

Zhou

2020

Mediators of Inflammation

View full text Add to dashboard Cite

show abstract

“…Use of LUTS/BPH-related medications increases with age, particularly among men aged 40 to 60 years. [ 3 ] Yet long-term clinical utility is limited because most patients discontinue these medications within the first year of initiating treatment due to intolerance or inadequate response. [ 4 – 6 ] For patients with bothersome LUTS who fail medical therapy, transurethral resection of the prostate (TURP) is often recommended since this surgery provides clinically meaningful and durable symptom relief.…”

Section: Introductionmentioning

confidence: 99%

Water vapor thermal therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia

et al. 2020

View full text Add to dashboard Cite

Background: Water vapor thermal therapy (WVTT) is a minimally invasive procedure for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH). There are no known systematic reviews reporting the effectiveness and safety of this increasingly common BPH therapy. Methods: We performed a systematic review and meta-analysis of studies utilizing WVTT for symptomatic BPH. The international prostate symptom score (IPSS), IPSS-quality of life (IPSS-QOL), BPH impact index (BPHII), and maximum flow rate (Qmax) were calculated as the weighted mean difference relative to baseline and reported in minimal clinically important difference (MCID) units. MCID thresholds were −3 for IPSS, −0.5 for IPSS-QOL, −0.5 for BPHII, and 2 mL/s for Qmax. The surgical retreatment rate was calculated using life-table methods. Results: We identified 5 cohorts treated with WVTT from 4 studies (514 patients; 40% with median lobe obstruction) with 2 years median follow-up (range: 6 months to 4 years). The IPSS, IPSS-QOL, BPHII, and Qmax significantly improved at all intervals between 3 months and 4 years; this benefit ranged from 3.3 to 3.8 MCID units for IPSS, 3.9 to 4.6 MCID units for IPSS-QOL, 6.8 to 8.2 MCID units for BPHII, and 1.5 to 3.0 MCID units for Qmax. The surgical retreatment rate was 7.0% at 4 years of follow-up data. Most adverse events were nonserious and transient; dysuria, urinary retention, and urinary tract infection were most common. No cases of de novo erectile dysfunction occurred. Conclusions: WVTT provided improvement in BPH symptoms that exceeded established MCID thresholds, preserved sexual function, and was associated with low surgical retreatment rates over 4 years.

show abstract

“…Benign prostatic hyperplasia (BPH) is the most common disease in older men ( Wei et al, 2008 ). BPH occurs in 15% to 60% of men over the age of 40 years and in more than 70% of men older than 70 years ( Parsons et al, 2008 ; Welliver et al, 2020 ). It usually occurs with lower urinary tract symptoms (LUTS) and seriously affects the quality of life of patients due to dysuria, nocturia, urinary retention and other symptoms ( Coyne et al, 2009 ; Wei et al, 2008 ; Welliver et al, 2020 ).…”

Section: Introductionmentioning

confidence: 99%

The role of macrophage migration inhibitory factor in promoting benign prostatic hyperplasia epithelial cell growth by modulating COX-2 and P53 signaling

et al. 2020

View full text Add to dashboard Cite

Inflammation and proinflammatory cytokines have been implicated in the progression of benign prostatic hyperplasia (BPH). Macrophage migration inhibitory factor (MIF) is a proinflammatory cytokine. Our previous study found that MIF is highly expressed in BPH epithelium. It has been reported that there is a correlation between MIF and clinical BPH progression. However, whether MIF has an effect on BPH epithelial cells is not clear. The aim of this study was to explore whether MIF has a role in BPH. Our results showed that IHC showed that MIF is highly expressed in the epithelium and that MIF and PCNA expression levels are higher in BPH samples than in control. CCK8 and flow cytometry assays showed that rMIF promoted the proliferation of BPH-1 and PWR-1E cells, while ISO-1 partially reversed this effect on proliferation. JC-1 assays showed that rMIF inhibited the apoptosis of BPH-1 and PWR-1E cells, and ISO-1 could partially reverse this inhibition. Moreover, western blotting indicated that rMIF downregulated P53 and upregulated COX-2. Furthermore, MIF-induced proliferation could be inhibited by celecoxib in the CCK8 and flow cytometry assay. MIF-inhibited apoptosis could be partially reversed by celecoxib in the JC-1 assay. Western blotting showed that celecoxib could partially reverse MIF-induced COX-2 upregulation and P53 downregulation. Together, MIF is highly expressed in BPH epithelium. In vitro, MIF promoted BPH epithelial cell growth by regulating COX-2 and P53 signaling. Targeting MIF may provide a new option for the improved treatment of BPH in the future.

show abstract

Trends in Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia, 2004 to 2013: the Urologic Diseases in America Project

Cited by 39 publications

References 0 publications

Review of the Roles and Interaction of Androgen and Inflammation in Benign Prostatic Hyperplasia

Review of the Roles and Interaction of Androgen and Inflammation in Benign Prostatic Hyperplasia

Water vapor thermal therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia

The role of macrophage migration inhibitory factor in promoting benign prostatic hyperplasia epithelial cell growth by modulating COX-2 and P53 signaling

Contact Info

Product

Resources

About